Iron Supplements Do Not Lower the Seizure Threshold
Iron supplements do not lower the seizure threshold; in fact, iron deficiency may paradoxically protect against seizures, particularly febrile seizures in children. The available evidence suggests that iron supplementation is safe in patients with epilepsy and does not increase seizure risk.
Evidence from Seizure Research
The most direct evidence addressing this question comes from a prospective study examining iron status in children with febrile seizures 1. This study found that children with febrile seizures were significantly less likely to be iron deficient compared to controls with fever but no seizures. Multiple iron deficiency markers showed this protective effect:
- Free erythrocyte protoporphyrin >0.80 ng/L: 2/23 in seizure group vs 10/25 in controls (p<0.01)
- Hemoglobin <110 g/L: 1/26 vs 6/25 (p<0.03)
- None of the febrile seizure patients were receiving iron supplementation, while 3/25 controls were (p<0.04)
The study concluded that iron deficiency may actually protect against febrile seizure development 1.
Iron Metabolism in Epilepsy
While abnormal iron metabolism has been associated with certain types of epilepsy (particularly post-hemorrhagic and post-traumatic epilepsy), this relates to iron overload and ferroptosis (iron-dependent cell death), not iron supplementation at therapeutic doses 2. The concern in epilepsy is excessive iron accumulation causing oxidative damage, not the therapeutic correction of iron deficiency.
Clinical Context from Guidelines
The guideline literature on iron supplementation makes no mention of seizure risk or lowered seizure threshold as a contraindication or adverse effect 3, 4, 5, 4, 5. The extensive safety discussions in these guidelines focus on:
- Anaphylaxis risk (particularly with certain IV formulations)
- Gastrointestinal side effects with oral iron
- Hypophosphatemia with certain IV formulations (particularly ferric carboxymaltose) 6
- Iron overload concerns
Seizures are notably absent from the adverse effect profiles across all iron formulation guidelines.
Special Consideration: 22q11.2 Deletion Syndrome
One guideline specifically addresses seizures in a genetic syndrome context 7. In 22q11.2 deletion syndrome, where seizures are common (5-7% lifetime prevalence vs 0.5-1% in general population), the guideline notes that hypocalcemia is a major seizure trigger and recommends calcium and vitamin D supplementation. Iron supplementation is not mentioned as problematic, and the standard caution about vitamin supplements with anticonvulsants refers to specific vitamin needs, not restrictions.
Practical Recommendations
For patients with epilepsy requiring iron supplementation:
- Proceed with standard iron supplementation protocols without concern for lowering seizure threshold
- Screen iron status routinely (ferritin, transferrin saturation, hemoglobin) 4
- Use oral iron (ferrous sulfate 100-200 mg/day in divided doses) as first-line 5
- Consider IV iron for:
Monitor for actual iron-related complications:
- Gastrointestinal side effects (consider alternate-day dosing for better tolerance) 4
- Hypophosphatemia if using ferric carboxymaltose 6
- Anaphylaxis risk with IV formulations (have resuscitation available) 5
Important Caveat
The one theoretical concern relates to iron overload states (not therapeutic supplementation), where excessive iron accumulation can contribute to oxidative neuronal damage and potentially worsen epilepsy through ferroptosis mechanisms 2. This is relevant in conditions like repeated transfusions or hereditary hemochromatosis, not in standard iron deficiency treatment.
Bottom line: Iron supplementation for documented iron deficiency is safe and appropriate in patients with epilepsy. There is no evidence that therapeutic iron supplementation lowers the seizure threshold or increases seizure frequency.